Case studies, method notes, and updates from Aiosyn.https://www.aiosyn.com/https://www.aiosyn.com/news/quantitative-image-analysis-dapagliflozin-diabetic-nephropathy-sdt-fatty-rat/https://www.aiosyn.com/news/quantitative-image-analysis-dapagliflozin-diabetic-nephropathy-sdt-fatty-rat/Published in the European Journal of Pharmaceutical Sciences: NephroPath AI quantified glomerulosclerosis and tubular impairment across whole kidney sections and resolved a dapagliflozin treatment effect that classical histopathological scoring did not detect.Wed, 17 Jun 2026 09:00:00 GMTCase studyResearchPatrick de Boerhttps://www.aiosyn.com/news/aiosyn-raises-2-million-in-new-funding-round/https://www.aiosyn.com/news/aiosyn-raises-2-million-in-new-funding-round/Aiosyn, a Dutch medical software company specializing in AI-powered pathology, has successfully closed a €2.4 million funding round. Participating investors are TNO Ventures, Oost NL, LUMO Labs, and Health Innovations.Tue, 09 Sep 2025 05:02:52 GMTCompanyPatrick de Boerhttps://www.aiosyn.com/news/aiosyn-and-telemis-advance-breast-cancer-diagnosis-with-ivdr-certified-ai-technology/https://www.aiosyn.com/news/aiosyn-and-telemis-advance-breast-cancer-diagnosis-with-ivdr-certified-ai-technology/The integration will enable labs to use Aiosyn Mitosis Breast, the first IVDR-certified breast cancer diagnosis AI tool for mitosis countingThu, 26 Jun 2025 09:58:35 GMTCompanyAnna Correas Grifollhttps://www.aiosyn.com/news/navigating-the-ivdr-how-aiosyn-prioritized-compliance-from-day-one/https://www.aiosyn.com/news/navigating-the-ivdr-how-aiosyn-prioritized-compliance-from-day-one/Aiosyn avoided the transition period to IVDR and potential delays by being IVDR-compliant from day one, ensuring smoother market access and increased credibilityMon, 26 May 2025 14:15:36 GMTBlogDiana Rosentulhttps://www.aiosyn.com/news/from-pixels-to-pathology-insights-integrating-aiosyns-ai-into-the-techcyte-fusion-platform/https://www.aiosyn.com/news/from-pixels-to-pathology-insights-integrating-aiosyns-ai-into-the-techcyte-fusion-platform/David Tellez joins Techcyte's Chief Medical Officer for a Pioneers in Digital Diagnostics session on running Aiosyn's quality control and mitosis counting inside the Techcyte Fusion platform.Tue, 29 Apr 2025 09:00:00 GMTEventAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyn-expands-ai-powered-quality-control-with-incomplete-scan-detection/https://www.aiosyn.com/news/aiosyn-expands-ai-powered-quality-control-with-incomplete-scan-detection/Aiosyn expands AI-powered artifact detection solution to detect incomplete scanning in digital histology slides.Wed, 09 Apr 2025 11:11:35 GMTProductAnna Correas Grifollhttps://www.aiosyn.com/news/techcyte-and-aiosyn-collaborate-to-integrate-ai-powered-slide-qc-and-mitotic-counting-into-the-fusion-digital-pathology-platform/https://www.aiosyn.com/news/techcyte-and-aiosyn-collaborate-to-integrate-ai-powered-slide-qc-and-mitotic-counting-into-the-fusion-digital-pathology-platform/Techcyte and Aiosyn announced a collaboration that brings Aisoyn’s AI algorithms to the Fusion digital pathology platform.Thu, 20 Mar 2025 12:07:40 GMTProductAnna Correas Grifollhttps://www.aiosyn.com/news/techcyte-pramana-and-aiosyn-collaborate-to-deliver-edge-ai-mitosis-detection-and-kidney-structure-analysis-into-the-techcyte-fusion-platform-2/https://www.aiosyn.com/news/techcyte-pramana-and-aiosyn-collaborate-to-deliver-edge-ai-mitosis-detection-and-kidney-structure-analysis-into-the-techcyte-fusion-platform-2/Techcyte, Pramana, and Aiosyn partner to provide edge AI mitosis and kidney structure detectionThu, 20 Mar 2025 12:05:35 GMTCompanyAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyn-and-pramana-introduce-real-time-ai-processing-for-kidney-biopsy-assessments/https://www.aiosyn.com/news/aiosyn-and-pramana-introduce-real-time-ai-processing-for-kidney-biopsy-assessments/Aiosyn and Pramana announced a collaboration to deliver inline AI detection of kidney structures in histology whole-slide images (WSIs).Tue, 18 Mar 2025 07:50:10 GMTCompanyAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyn-enhances-its-ai-powered-quality-control-solution-to-detect-white-balance-issues/https://www.aiosyn.com/news/aiosyn-enhances-its-ai-powered-quality-control-solution-to-detect-white-balance-issues/Nijmegen, the Netherlands – Aiosyn, a pioneering innovator in AI-powered pathology software for cancer and kidney disease, has announced the latest advancement in its automated quality control (QC) algorithm.Wed, 05 Feb 2025 11:11:38 GMTProductAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyn-s-kidney-image-analysis-tools-are-now-available-on-histowiz-s-pathologymap/https://www.aiosyn.com/news/aiosyn-s-kidney-image-analysis-tools-are-now-available-on-histowiz-s-pathologymap/Nijmegen, the Netherlands – Aiosyn, a pioneering innovator in AI-powered pathology software for cancer and kidney disease, is thrilled to announce the integration of its NephroPath AI tools into HistoWiz’s PathologyMap™ platform. This collaboration provides researchers using PathologyMap™ with state-of-the-art solutions for kidney tissue analysis, facilitating and accelerating scientific research.Tue, 28 Jan 2025 12:52:55 GMTProductAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyn-mitosis-breast-becomes-the-first-ai-powered-mitosis-detection-solution-to-achieve-ce-mark-certification-under-ivdr/https://www.aiosyn.com/news/aiosyn-mitosis-breast-becomes-the-first-ai-powered-mitosis-detection-solution-to-achieve-ce-mark-certification-under-ivdr/Aiosyn’s algorithm for breast mitosis detection has achieved CE marking under the IVDR for use in diagnostics.Tue, 07 Jan 2025 13:09:14 GMTCompanyAnna Correas Grifollhttps://www.aiosyn.com/news/case-study-automating-radboudumcs-digital-slide-quality-control-with-aiosynqc/https://www.aiosyn.com/news/case-study-automating-radboudumcs-digital-slide-quality-control-with-aiosynqc/Case study showcasing how Radboudumc is leveraging AiosynQC, an automated quality control solution for artifact detection in histology slidesThu, 19 Dec 2024 09:15:08 GMTCase studyAnna Correas Grifollhttps://www.aiosyn.com/news/leveraging-ai-for-quantitative-assessments-of-kidney-health-in-diabetic-animal-models/https://www.aiosyn.com/news/leveraging-ai-for-quantitative-assessments-of-kidney-health-in-diabetic-animal-models/Physiogenex uses NephroPath's automated kidney pathology analysis to assess Dapagliflozin's efficacy, providing precise data on kidney damageThu, 12 Dec 2024 12:00:07 GMTCase studyAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyn-launches-aiosynqc-pulse-for-external-digital-slide-quality-assessments-providing-pathology-labs-with-insights-for-slide-quality-improvement/https://www.aiosyn.com/news/aiosyn-launches-aiosynqc-pulse-for-external-digital-slide-quality-assessments-providing-pathology-labs-with-insights-for-slide-quality-improvement/Nijmegen, the Netherlands – Aiosyn, a pioneering innovator in AI-powered pathology software for cancer and kidney disease, has introduced its external digital slide quality assessments to support laboratories in achieving good-quality histology slides—essential for accurate pathology diagnoses.Wed, 27 Nov 2024 13:02:49 GMTProductAnna Correas Grifollhttps://www.aiosyn.com/news/aiosynqc-webinar-enhancing-digital-pathology-workflows-with-ai-powered-quality-control/https://www.aiosyn.com/news/aiosynqc-webinar-enhancing-digital-pathology-workflows-with-ai-powered-quality-control/Watch our 45-minute webinar on the challenges of manual quality control (QC) in digital pathology, and how AI-powered technology changes that process.Tue, 05 Nov 2024 09:00:00 GMTEventAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyn-s-nephropath-quantitative-image-analysis-featured-in-physiogenex-s-research-posters-at-asn-kidney-week/https://www.aiosyn.com/news/aiosyn-s-nephropath-quantitative-image-analysis-featured-in-physiogenex-s-research-posters-at-asn-kidney-week/Aiosyn’s NephroPath platform* was highlighted at ASN Kidney Week 2024 in San Diego, as our partner Physiogenex presented research that leveraged our AI-powered image analysis technology to assess drug efficacy in preclinical kidney models.Fri, 01 Nov 2024 15:51:30 GMTEventCase studyAnna Correas Grifollhttps://www.aiosyn.com/news/convolutional-neural-networks-for-the-evaluation-of-chronic-and-inflammatory-lesions-in-kidney-transplant-biopsies-2-2-2/https://www.aiosyn.com/news/convolutional-neural-networks-for-the-evaluation-of-chronic-and-inflammatory-lesions-in-kidney-transplant-biopsies-2-2-2/Our aim was to validate and optimize a rat model of IgA nephropathy for drug efficacy studies using quantitative image analysis of kidney. To demonstrate the accuracy of our imaging methods, we evaluated atrasentan, a selective Endothelin A Receptor Antagonist currently evaluated in phase III clinical trials.Sat, 26 Oct 2024 10:00:09 GMTResearchCase studyThomas de Belhttps://www.aiosyn.com/news/convolutional-neural-networks-for-the-evaluation-of-chronic-and-inflammatory-lesions-in-kidney-transplant-biopsies-2-2-2-2/https://www.aiosyn.com/news/convolutional-neural-networks-for-the-evaluation-of-chronic-and-inflammatory-lesions-in-kidney-transplant-biopsies-2-2-2-2/We aimed to optimize drug efficacy studies in the Spontaneously Diabetic Torii (SDT) fatty rat, a type 2 diabetic model, using quantitative image analysis of kidney. To demonstrate the accuracy of our imaging methods, dapagliflozin (DAPA) was evaluated in SDT fatty rats with unilateral nephrectomy (Unx).Sat, 26 Oct 2024 10:00:07 GMTResearchCase studyBłażej Dolickihttps://www.aiosyn.com/news/ai-act-and-digital-pathology/https://www.aiosyn.com/news/ai-act-and-digital-pathology/This year marked a significant advancement in the regulation of AI-powered devices within the European market with the introduction of the AI Act.Wed, 25 Sep 2024 12:00:13 GMTBlogAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyn-s-nephropath-glomerucount-introduces-ai-powered-kidney-image-analysis-to-sectra-amplifier-marketplace/https://www.aiosyn.com/news/aiosyn-s-nephropath-glomerucount-introduces-ai-powered-kidney-image-analysis-to-sectra-amplifier-marketplace/NIJMEGEN, the Netherlands – Aiosyn, a pioneering pathology software company specializing in AI-powered solutions for kidney disease and breast cancer, has integrated its glomerular quantification algorithm with Sectra’s diagnostic application for pathology.Wed, 18 Sep 2024 10:37:05 GMTProductAnna Correas Grifollhttps://www.aiosyn.com/news/ai-assistance-in-chronic-kidney-disease-monitoring/https://www.aiosyn.com/news/ai-assistance-in-chronic-kidney-disease-monitoring/Utilizing AI kidney disease models for biopsy analysis can ensure that even slight deviations from normal kidney function are flagged.Wed, 03 Jul 2024 10:01:09 GMTProductAnna Correas Grifollhttps://www.aiosyn.com/news/behind-the-scenes-of-pathology-ai-innovation-blazej-dolickis-insights-into-training-validation-deployment-and-beyond/https://www.aiosyn.com/news/behind-the-scenes-of-pathology-ai-innovation-blazej-dolickis-insights-into-training-validation-deployment-and-beyond/After joining the team in 2022, Blazej has played a crucial role in developing and training Aiosyn’s products, particularly AiosynQC.Tue, 18 Jun 2024 10:24:13 GMTBlogVictoria Grosuhttps://www.aiosyn.com/news/discover-the-clinical-performance-results-of-aiosyn-mitosis-breast-at-ecdp-2024/https://www.aiosyn.com/news/discover-the-clinical-performance-results-of-aiosyn-mitosis-breast-at-ecdp-2024/Benefits of AI-assisted mitotic count with Aiosyn Mitosis Breast evaluated in a multi-center clinical study - ECDP 2024 presentation.Mon, 03 Jun 2024 12:29:14 GMTEventVictoria Grosuhttps://www.aiosyn.com/news/aiosyn-and-histowiz-partner-to-improve-kidney-disease-research-through-ai-powered-preclinical-studies/https://www.aiosyn.com/news/aiosyn-and-histowiz-partner-to-improve-kidney-disease-research-through-ai-powered-preclinical-studies/NETHERLANDS and NEW YORK CITY – Aiosyn, a pioneering pathology software company specializing in AI-powered solutions for cancer and kidney disease, and HistoWiz, a leading provider of histology and slide archiving services, today announced a pilot study to evaluate the benefits.Wed, 22 May 2024 11:41:36 GMTCompanyAnna Correas Grifollhttps://www.aiosyn.com/news/the-history-of-pathology-origins-early-days-and-the-transition-to-novel-technologies/https://www.aiosyn.com/news/the-history-of-pathology-origins-early-days-and-the-transition-to-novel-technologies/Throughout history, pathology has remained an integral component of medicine, tracing its origins to ancient healers recognizing the importance of understanding disease processes for effective treatments.Thu, 16 May 2024 11:24:59 GMTBlogAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyns-ai-powered-mitosis-detection-solution-is-now-accessible-on-sectra-amplifier-marketplace/https://www.aiosyn.com/news/aiosyns-ai-powered-mitosis-detection-solution-is-now-accessible-on-sectra-amplifier-marketplace/Aiosyn Mitosis Breast is available on Sectra’s digital pathology solution to support pathologists with mitosis identification in breast WSIs.Thu, 02 May 2024 09:45:46 GMTProductAnna Correas Grifollhttps://www.aiosyn.com/news/the-benefits-of-ai-implementation-in-mitotic-figure-counting/https://www.aiosyn.com/news/the-benefits-of-ai-implementation-in-mitotic-figure-counting/In this blog article, we explore how AI can contribute to improving the consistency and efficiency of mitosis count assessments.Thu, 11 Apr 2024 14:41:09 GMTBlogVictoria Grosuhttps://www.aiosyn.com/news/ai-assisted-mitosis-counting-in-breast-cancer-a-large-scale-validation-study/https://www.aiosyn.com/news/ai-assisted-mitosis-counting-in-breast-cancer-a-large-scale-validation-study/Aiosyn's breast cancer AI solution for mitosis counting shows improved grading consistency and efficiency.Mon, 25 Mar 2024 16:52:09 GMTResearchProductDavid Tellezhttps://www.aiosyn.com/news/zas-netwerk-partners-with-aiosyn-to-evaluate-ai-powered-mitosis-detection-in-clinical-settings/https://www.aiosyn.com/news/zas-netwerk-partners-with-aiosyn-to-evaluate-ai-powered-mitosis-detection-in-clinical-settings/ZAS Netwerk partners with Aiosyn to evaluate deep-learning breast cancer mitosis detection in clinical settings.Mon, 25 Mar 2024 14:28:24 GMTCompanyAnna Correas Grifollhttps://www.aiosyn.com/news/explore-the-clinical-performance-insights-of-aiosyn-mitosis-breast-at-uscap-2024/https://www.aiosyn.com/news/explore-the-clinical-performance-insights-of-aiosyn-mitosis-breast-at-uscap-2024/Aiosyn, a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney diseases, recently conducted a clinical performance study in collaboration with Radboud university medical center.Thu, 21 Mar 2024 14:26:14 GMTEventVictoria Grosuhttps://www.aiosyn.com/news/aiosyn-and-physiogenex-partner-to-enhance-kidney-disease-drug-development/https://www.aiosyn.com/news/aiosyn-and-physiogenex-partner-to-enhance-kidney-disease-drug-development/Nijmegen, The Netherlands – Aiosyn, a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney disease, has announced a collaboration with Physiogenex, a leading preclinical Contract Research Organization (CRO) specializing in metabolic diseases.Thu, 14 Mar 2024 14:21:38 GMTCompanyAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyn-launches-kidney-image-analysis-services-through-its-nephropath-platform-to-accelerate-drug-development-studies/https://www.aiosyn.com/news/aiosyn-launches-kidney-image-analysis-services-through-its-nephropath-platform-to-accelerate-drug-development-studies/Nijmegen, Netherlands – Aiosyn, a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney disease, announced the introduction of its NephroPath platform.Thu, 29 Feb 2024 14:14:20 GMTProductPatrick de Boerhttps://www.aiosyn.com/news/aiosyn-partners-with-paige-to-enhance-the-accessibility-of-ai-powered-automated-quality-control-in-pathology-laboratories-worldwide/https://www.aiosyn.com/news/aiosyn-partners-with-paige-to-enhance-the-accessibility-of-ai-powered-automated-quality-control-in-pathology-laboratories-worldwide/Nijmegen, the Netherlands – Aiosyn, a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney disease, has announced a distribution collaboration with Paige, a global leader in AI-based diagnostic software in pathology.Thu, 08 Feb 2024 14:07:06 GMTCompanyAnna Correas Grifollhttps://www.aiosyn.com/news/diana-rosentul-explains-the-complexities-of-regulatory-compliance-for-integrating-ai-based-solutions-in-the-healthcare-industry/https://www.aiosyn.com/news/diana-rosentul-explains-the-complexities-of-regulatory-compliance-for-integrating-ai-based-solutions-in-the-healthcare-industry/Diana Rosentul, a Regulatory Affairs Specialist at Aiosyn, intricately manages the regulatory landscape associated with the integration of AI-based solutions within clinical and research institutions.Thu, 25 Jan 2024 14:34:18 GMTBlogDiana Rosentulhttps://www.aiosyn.com/news/cristina-gonzalez-gonzalo-discusses-her-journey-with-the-clinical-validation-of-aiosyn-mitosis-breast/https://www.aiosyn.com/news/cristina-gonzalez-gonzalo-discusses-her-journey-with-the-clinical-validation-of-aiosyn-mitosis-breast/Cristina González Gonzalo, Clinical Program Manager at Aiosyn, shares her experiences from the clinical validation of Aiosyn Mitosis Breast.Thu, 14 Dec 2023 14:26:02 GMTBlogAnna Correas Grifollhttps://www.aiosyn.com/news/time-to-go-digital-navigating-the-pathology-transition-from-microscopes-to-whole-slide-images/https://www.aiosyn.com/news/time-to-go-digital-navigating-the-pathology-transition-from-microscopes-to-whole-slide-images/We have witnessed technology adoption in nearly every industry through the digitization of manual tasks. Pathology laboratories are no exception, and we are also observing a transition to digital workflows in this field.Thu, 30 Nov 2023 13:33:00 GMTBlogVictoria Grosuhttps://www.aiosyn.com/news/aiosyn-announces-the-formation-of-a-scientific-advisory-board-to-guide-the-continued-development-of-its-kidney-ai-suite/https://www.aiosyn.com/news/aiosyn-announces-the-formation-of-a-scientific-advisory-board-to-guide-the-continued-development-of-its-kidney-ai-suite/Nijmegen, The Netherlands – Aiosyn, a medical software company specializing in AI-powered pathology solutions for cancer and kidney diseases, has announced the formation of its Scientific Advisory Board.Thu, 12 Oct 2023 10:07:19 GMTCompanyAnna Correas Grifollhttps://www.aiosyn.com/news/prepare-for-the-future-ai-is-changing-the-landscape-of-pathology/https://www.aiosyn.com/news/prepare-for-the-future-ai-is-changing-the-landscape-of-pathology/The recent advancements in artificial intelligence (AI) have ignited excitement regarding its potential applications in the field of pathology. Evidence is accumulating that AI can make diagnoses more accurate, efficient, and standardized.Mon, 09 Oct 2023 14:30:05 GMTBlogVictoria Grosuhttps://www.aiosyn.com/news/aiosyn-introduces-kidney-ai-platform-to-revolutionize-renal-disease-research/https://www.aiosyn.com/news/aiosyn-introduces-kidney-ai-platform-to-revolutionize-renal-disease-research/Nijmegen, Netherlands – Aiosyn, a medical software company specializing in AI-powered pathology solutions, has announced the release of an AI kidney suite designed to advance research in the field of renal disease.Mon, 18 Sep 2023 10:54:55 GMTProductAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyn-unveils-first-results-of-independent-clinical-study-improved-efficiency-and-consistency-in-mitosis-counting-with-aiosyn-mitosis-breast/https://www.aiosyn.com/news/aiosyn-unveils-first-results-of-independent-clinical-study-improved-efficiency-and-consistency-in-mitosis-counting-with-aiosyn-mitosis-breast/Nijmegen, the Netherlands – Aiosyn is proud to announce the first results of an independent clinical performance study conducted for its Aiosyn Mitosis Breast solution.Sun, 10 Sep 2023 12:16:21 GMTProductAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyn-radboud-university-medical-center-nki-mayo-clinic-and-partners-have-been-awarded-1-8m-kwf-grant-to-deliver-artificial-intelligence-based-assessment-of-existing-and-new-histopathological-bio/https://www.aiosyn.com/news/aiosyn-radboud-university-medical-center-nki-mayo-clinic-and-partners-have-been-awarded-1-8m-kwf-grant-to-deliver-artificial-intelligence-based-assessment-of-existing-and-new-histopathological-bio/Nijmegen, the Netherlands – Aiosyn, a medical software company that develops AI-powered pathology solutions, has been awarded the prestigious KWF (Dutch Cancer Society) grant as part of an international consortium in collaboration with Radboud university medical center, Mayo Clinic, Netherlands Cancer Institute (NKI), APSS Hospital, UNIBS Hospital, IRCC Hospital, German Breast Group, and the Medical University Vienna.Mon, 04 Sep 2023 11:32:48 GMTCompanyAnna Correas Grifollhttps://www.aiosyn.com/news/how-automated-quality-control-of-whole-slide-images-can-increase-the-efficiency-of-clinical-and-research-pathology-workflows/https://www.aiosyn.com/news/how-automated-quality-control-of-whole-slide-images-can-increase-the-efficiency-of-clinical-and-research-pathology-workflows/This article explores how automated quality control algorithms have the potential to significantly accelerate histopathology workflows.Tue, 25 Jul 2023 09:06:47 GMTBlogVictoria Grosuhttps://www.aiosyn.com/news/the-digital-revolution-in-pathology-the-power-of-ai-in-computational-pathology/https://www.aiosyn.com/news/the-digital-revolution-in-pathology-the-power-of-ai-in-computational-pathology/Artificial intelligence is empowering pathologists and improving diagnostics. In the era of rapid AI advancement, a question often arises: will AI replace human jobs?Mon, 26 Jun 2023 12:24:50 GMTBlogVictoria Grosuhttps://www.aiosyn.com/news/aiosyn-launches-ai-powered-mitosis-detection-solution-to-support-cancer-research-improving-the-efficiency-and-consistency-of-results/https://www.aiosyn.com/news/aiosyn-launches-ai-powered-mitosis-detection-solution-to-support-cancer-research-improving-the-efficiency-and-consistency-of-results/Nijmegen – Aiosyn, a medical software company specializing in AI-powered pathology solutions, released its first AI algorithm in its Mitosis product family: Aiosyn Mitosis Research. The innovative deep-learning algorithm is designed to automatically scan for cells undergoing division (mitoses).Tue, 20 Jun 2023 12:08:06 GMTProductAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyn-expands-its-ai-powered-quality-control-solution-for-digital-pathology-slides-to-support-immunohistochemistry-ihc-staining/https://www.aiosyn.com/news/aiosyn-expands-its-ai-powered-quality-control-solution-for-digital-pathology-slides-to-support-immunohistochemistry-ihc-staining/Nijmegen, Netherlands – Aiosyn, a software company that develops AI-powered pathology solutions, has announced the latest advancement in their automated quality control (QC) algorithm.Wed, 14 Jun 2023 08:40:00 GMTProductAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyn-radboudumc-and-pathologie-dna-are-awarded-a-eur-1-3m-efro-grant-to-develop-ai-powered-solutions-for-cancer-diagnostics/https://www.aiosyn.com/news/aiosyn-radboudumc-and-pathologie-dna-are-awarded-a-eur-1-3m-efro-grant-to-develop-ai-powered-solutions-for-cancer-diagnostics/Nijmegen, the Netherlands – Aiosyn, a medical software company that develops AI-powered pathology solutions, has been awarded a EUR 1.300.000 EFRO-OOST grant alongside Radboud university medical center and Pathologie-DNA to accelerate the development of AI technology for breast and skin cancer diagnostics.Tue, 09 May 2023 12:53:59 GMTCompanyAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyns-ai-powered-quality-control-for-digital-pathology-slides-is-now-available-in-sectra-amplifier-marketplace/https://www.aiosyn.com/news/aiosyns-ai-powered-quality-control-for-digital-pathology-slides-is-now-available-in-sectra-amplifier-marketplace/Nijmegen, the Netherlands – Aiosyn, a software company that develops AI-powered pathology software, has announced the integration of its AI-powered automated quality control (QC) algorithm in the Sectra Amplifier Marketplace.Sat, 06 May 2023 07:55:53 GMTProductAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyn-pathomation-and-radboud-university-medical-center-are-awarded-16m-e-eurostars-grant-to-develop-ai-powered-solutions-for-renal-diagnostics/https://www.aiosyn.com/news/aiosyn-pathomation-and-radboud-university-medical-center-are-awarded-16m-e-eurostars-grant-to-develop-ai-powered-solutions-for-renal-diagnostics/Nijmegen, the Netherlands – Aiosyn, a medical software company that develops AI-powered pathology solutions, has been awarded a 1,6M € Eurostars grant together with Pathomation and Radboud university medical center to accelerate the development of a Kidney-AI algorithm suite.Wed, 05 Apr 2023 13:42:12 GMTCompanyAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyn-launches-ai-powered-automated-quality-control-to-improve-the-digital-pathology-workflow/https://www.aiosyn.com/news/aiosyn-launches-ai-powered-automated-quality-control-to-improve-the-digital-pathology-workflow/Nijmegen, the Netherlands – Aiosyn, a software company that develops AI-powered pathology software, has launched its first product that assists digital pathology labs across research, diagnostics and pharma to improve their quality control (QC) process. AiosynQC is an AI-powered algorithm.Fri, 10 Mar 2023 17:08:17 GMTProductAnna Correas Grifollhttps://www.aiosyn.com/news/aiosyn-raises-2-million-in-new-investment-round/https://www.aiosyn.com/news/aiosyn-raises-2-million-in-new-investment-round/Aiosyn is developing a diagnostics platform that uses artificial intelligence to support pathologists with more accurate and efficient clinical diagnostics. A new investment round of EUR 2 million, led by Health Innovations together with Oost NL and LUMO Labs, enables Aiosyn to further develop their platform and accelerate the time to market.Wed, 21 Dec 2022 09:09:48 GMTCompanyWouter Bultenhttps://www.aiosyn.com/news/aiosyn-haalt-2-miljoen-euro-op-in-investeringsronde/https://www.aiosyn.com/news/aiosyn-haalt-2-miljoen-euro-op-in-investeringsronde/Nijmegen, Nederland – Aiosyn ontwikkelt een diagnostisch platform dat kunstmatige intelligentie gebruikt om pathologen te ondersteunen met nauwkeurigere en efficiëntere klinische diagnostiek. Een nieuwe investeringsronde van 2 miljoen euro, geleid door Health Innovations samen met Oost NL en LUMO Labs.Wed, 21 Dec 2022 09:09:05 GMTCompanyPatrick de Boerhttps://www.aiosyn.com/news/aiosyn-achieves-iso13485-certification/https://www.aiosyn.com/news/aiosyn-achieves-iso13485-certification/Nijmegen – Aiosyn, a medical software company that develops AI-powered pathology software, has achieved ISO:13485 certification, after successfully auditing its Quality Management System (QMS) by The British Standards Institution (BSI). Achieving this certification demonstrates Aiosyn's commitment to producing high-quality AI-powered medical devices for pathology.Mon, 12 Dec 2022 09:47:52 GMTCompanyWouter Bultenhttps://www.aiosyn.com/news/convolutional-neural-networks-for-the-evaluation-of-chronic-and-inflammatory-lesions-in-kidney-transplant-biopsies-2-2/https://www.aiosyn.com/news/convolutional-neural-networks-for-the-evaluation-of-chronic-and-inflammatory-lesions-in-kidney-transplant-biopsies-2-2/This study investigates the potential of CNNs (AI) to quantify inflammation and chronic features in kidney transplant biopsies.Sat, 01 Oct 2022 14:50:38 GMTResearchJeroen van der Laakhttps://www.aiosyn.com/news/aiosyn-radboudumc-implement-ai-clinical-workflow/https://www.aiosyn.com/news/aiosyn-radboudumc-implement-ai-clinical-workflow/Aiosyn, a company that develops AI-powered computational pathology analysis for clinical diagnostics, and the department of pathology of Radboud University Medical Center, will collaborate to implement an algorithm for quality control of digitized histopathology tissue slides.Mon, 04 Apr 2022 10:10:20 GMTCompanyPatrick de Boerhttps://www.aiosyn.com/news/lumo-labs-pre-seed-round-aiosyn/https://www.aiosyn.com/news/lumo-labs-pre-seed-round-aiosyn/Nijmegen, The Netherlands – LUMO Labs’ pre-seed investment vehicle LUMO Fund II TTT AI announces an investment in Aiosyn B.V.. Aiosyn’s clinical diagnostics platform uses AI-powered pathology algorithms to support pathologists with more accurate and efficient clinical decision-making.Thu, 03 Feb 2022 15:25:00 GMTCompanyPatrick de Boerhttps://www.aiosyn.com/news/investering-in-aiosyn-ai-platform/https://www.aiosyn.com/news/investering-in-aiosyn-ai-platform/Nijmegen – Aiosyn, een spin-out van het Radboud Universitair Medisch Centrum, heeft een investering opgehaald. Het bedrijf ontwikkelt een diagnostiek platform dat gebruik maakt van AI om pathologen te ondersteunen met meer preciezere en efficiënte klinische diagnoses.Thu, 03 Feb 2022 08:20:00 GMTCompanyPatrick de Boerhttps://www.aiosyn.com/news/artificial-intelligence-for-diagnosis-and-gleason-grading-of-prostate-cancer-the-panda-challenge-2/https://www.aiosyn.com/news/artificial-intelligence-for-diagnosis-and-gleason-grading-of-prostate-cancer-the-panda-challenge-2/Artificial intelligence (AI) has shown promise for diagnosing prostate cancer in biopsies. However, results have been limited to individual studies, lacking validation in multinational settings.Thu, 13 Jan 2022 08:50:01 GMTResearchWouter Bultenhttps://www.aiosyn.com/news/take-off-2-early-phase-funding/https://www.aiosyn.com/news/take-off-2-early-phase-funding/Aiosyn, a company that develops AI-powered pathology algorithms for clinical diagnostics and life sciences, was awarded early-phase funding of Eur 250.000 by NWO (Dutch Research Council).Wed, 22 Dec 2021 08:25:00 GMTCompanyWouter Bultenhttps://www.aiosyn.com/news/ppp-project-improving-breast-and-prostate-cancer-grading/https://www.aiosyn.com/news/ppp-project-improving-breast-and-prostate-cancer-grading/Aiosyn, a company that develops AI-powered pathology algorithms, will participate in an Health~Holland PPP Allowance project with the main aim to improve the diagnostic process for breast and prostate cancer grading. Providing the right care for prostate cancer patients is hampered by variability in assigning the histopathological Gleason grade.Tue, 23 Nov 2021 08:28:00 GMTCompanyJeroen van der Laakhttps://www.aiosyn.com/news/techleap-pole-position/https://www.aiosyn.com/news/techleap-pole-position/Aiosyn develops, integrates and certifies AI solutions that empower pathologists to make their clinical decisions in a more accurate, efficient and effective way, for the benefit of patients and society. We are thrilled and excited to have been selected for the first edition of Techleap's Pole Position.Tue, 19 Oct 2021 08:29:00 GMTCompanyDavid Tellezhttps://www.aiosyn.com/news/new-startup-aiosyn-press-release/https://www.aiosyn.com/news/new-startup-aiosyn-press-release/Aiosyn is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Aiosyn is a spin-off from Radboudumc, a frontrunner in computational pathology research.Tue, 21 Sep 2021 08:31:00 GMTCompanyPatrick de Boerhttps://www.aiosyn.com/news/start-up-aiosyn-ontwikkelt-ai-innovaties-voor-de-patholoog/https://www.aiosyn.com/news/start-up-aiosyn-ontwikkelt-ai-innovaties-voor-de-patholoog/Aiosyn wil de toepassing van kunstmatige intelligentie (AI) in de pathologie versnellen en de kansen van kankerpatiënten wereldwijd verbeteren. Aiosyn is een spin-off van het Radboudumc, koploper in het onderzoek naar AI binnen de pathologie.Tue, 21 Sep 2021 08:30:00 GMTCompanyPatrick de Boerhttps://www.aiosyn.com/news/digital-pathology-workflow-ai-for-life-podcast/https://www.aiosyn.com/news/digital-pathology-workflow-ai-for-life-podcast/Aiosyn’s CEO, Patrick de Boer, was a guest in the seventh edition of the AI for Life podcast to discuss introduction of AI in the digital pathology workflow. [Only Dutch version available]Mon, 28 Jun 2021 08:36:00 GMTEventPatrick de Boerhttps://www.aiosyn.com/news/deep-learning-in-histopathology-the-path-to-the-clinic/https://www.aiosyn.com/news/deep-learning-in-histopathology-the-path-to-the-clinic/Machine learning techniques have great potential to improve medical diagnostics, offering ways to improve accuracy, reproducibility and speed, and to ease workloads for clinicians.Fri, 14 May 2021 10:20:00 GMTResearchJeroen van der Laakhttps://www.aiosyn.com/news/deep-learning-enables-fully-automated-mitotic-density-assessment-in-breast-cancer-histopathology/https://www.aiosyn.com/news/deep-learning-enables-fully-automated-mitotic-density-assessment-in-breast-cancer-histopathology/Mitosis counting is an important part of breast cancer grading, yet known to suffer from observer variability. Advances in machine learning enable fully automated analysis of digitized glass slides.Thu, 01 Oct 2020 09:26:00 GMTResearchDavid Tellezhttps://www.aiosyn.com/news/artificial-intelligence-assistance-significantly-improves-gleason-grading-of-prostate-biopsies-by-pathologists/https://www.aiosyn.com/news/artificial-intelligence-assistance-significantly-improves-gleason-grading-of-prostate-biopsies-by-pathologists/The Gleason score is the most important prognostic marker for prostate cancer patients, but it suffers from significant observer variability. Artificial intelligence (AI) systems based on deep learning can achieve pathologist-level performance at Gleason grading.Wed, 05 Aug 2020 12:15:00 GMTResearchWouter Bultenhttps://www.aiosyn.com/news/automated-deep-learning-system-for-gleason-grading-of-prostate-cancer-using-biopsies-a-diagnostic-study/https://www.aiosyn.com/news/automated-deep-learning-system-for-gleason-grading-of-prostate-cancer-using-biopsies-a-diagnostic-study/The Gleason score is the strongest correlating predictor of recurrence for prostate cancer, but has substantial inter-observer variability, limiting its usefulness for individual patients. Specialised urological pathologists have greater concordance; however, such expertise is not widely available.Sat, 01 Feb 2020 13:48:00 GMTResearchWouter Bultenhttps://www.aiosyn.com/news/deep-learning-based-histopathologic-assessment-of-kidney-tissue/https://www.aiosyn.com/news/deep-learning-based-histopathologic-assessment-of-kidney-tissue/Histopathologic assessment of kidney tissue currently relies on manual scoring or traditional image-processing techniques to quantify and classify tissue features, time-consuming approaches that have limited reproducibility.Tue, 01 Oct 2019 14:57:08 GMTResearchJeroen van der Laakhttps://www.aiosyn.com/news/detecting-lymphocytes-in-immunohistochemistry-medical-image-analysis-2019/https://www.aiosyn.com/news/detecting-lymphocytes-in-immunohistochemistry-medical-image-analysis-2019/The immune system is of critical importance in the development of cancer. The evasion of destruction by the immune system is one of the emerging hallmarks of cancer.Wed, 21 Aug 2019 14:58:00 GMTResearchJeroen van der Laakhttps://www.aiosyn.com/news/quantifying-the-effects-of-data-augmentation-and-stain-color-normalization-in-convolutional-neural-networks-for-computational-pathology/https://www.aiosyn.com/news/quantifying-the-effects-of-data-augmentation-and-stain-color-normalization-in-convolutional-neural-networks-for-computational-pathology/Stain variation is a phenomenon observed when distinct pathology laboratories stain tissue slides that exhibit similar but not identical color appearance.Wed, 21 Aug 2019 02:53:04 GMTResearchDavid Tellezhttps://www.aiosyn.com/news/neural-image-compression-transactions-on-pattern-analysis-and-machine-intelligence-2019/https://www.aiosyn.com/news/neural-image-compression-transactions-on-pattern-analysis-and-machine-intelligence-2019/We propose Neural Image Compression (NIC), a two-step method to build convolutional neural networks for gigapixel image analysis solely using weak image-level labels.Thu, 28 Mar 2019 14:53:00 GMTResearchDavid Tellezhttps://www.aiosyn.com/news/whole-slide-mitosis-detection-in-he-breast-histology-using-phh3-as-a-reference-to-train-distilled-stain-invariant-convolutional-networks/https://www.aiosyn.com/news/whole-slide-mitosis-detection-in-he-breast-histology-using-phh3-as-a-reference-to-train-distilled-stain-invariant-convolutional-networks/Manual counting of mitotic tumor cells in tissue sections constitutes one of the strongest prognostic markers for breast cancer. This procedure, however, is time-consuming and error-prone.Wed, 28 Mar 2018 17:30:53 GMTResearchDavid Tellezhttps://www.aiosyn.com/news/camelyon-challenges/https://www.aiosyn.com/news/camelyon-challenges/Application of deep learning algorithms to whole-slide pathology images can potentially improve diagnostic accuracy and efficiency.Tue, 28 Mar 2017 09:33:00 GMTResearchJeroen van der Laak